Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Miami

Criteria

Inclusion Criteria:

• Healthy subjects,

• 18 years of age or older,

• with Fitzpatrick skin types II and III.

Exclusion Criteria:

• Pregnancy

• Personal history of skin cancer

• History of abnormal photosensitivity

• Smokers

• Patients with history or being exposed to other forms of radiation (other than sunlight)

• History or current exposure to asbestos

• Patients taking any drug that might alter the response of skin to UVR (including, but are not limited to, doxycycline, sulfas, psoralens, and amiodarone)

• Patients unable to undergo skin biopsies

• History of abnormal scarring

• History of adverse reaction to local anesthesia